Neumora (NMRA) Q2 Loss Improves 10%
Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline. Neumora reported a net loss per share of $(0.33), an improvement from $(0.37) the prior year. Overall, the period reflected careful financial management and steady pipeline progress, but continued high cash usage and dependence on future clinical outcomes.
Source: Analyst estimates for the quarter provided by FactSet.
Neumora Therapeutics is focused on discovering, developing, and commercializing therapies for brain diseases using a precision neuroscience approach. Its programs target high-prevalence conditions such as major depressive disorder (MDD), agitation in Alzheimer’s disease, schizophrenia, and obesity. Instead of a one-size-fits-all model, it uses advanced data science and artificial intelligence to pinpoint and monitor patient subgroups for better trial outcomes and future treatment matching.
Source Fool.com
